Evidence mapPaperPMID 17599428Full record

Trial reportThe American journal of cardiology2007

Severe hypoglycemia monitoring and risk management procedures in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.

Denise E Bonds, Ella Mae Kurashige, Richard Bergenstal, David Brillon, Michael Domanski, James V Felicetta, Vivian A Fonseca, Kathleen Hall, Irene Hramiak, Michael E Miller and 3 more

Registry-linked trialOpen access · bronzeAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in The American journal of cardiology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT00000620. Cited by 27 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 3 pooled it
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00000620 phase3completed

Action to Control Cardiovascular Risk in Diabetes (ACCORD)

Ran1999Enrolled10,251Registered outcomes6Posted comparisons6ConditionsAtherosclerosis, Cardiovascular Diseases, Coronary Disease, Diabetes MellitusArmsAnti-hyperglycemic Agents, Anti-hypertensive Agents, Blinded fenofibrate or placebo plus simvastatin
Open the trial in the graph
3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 3 syntheses or guidelines pooled it, 52 citations in OpenAlex.

  1. Pooled it
  2. Glucose targets for preventing diabetic kidney disease and its progression.The Cochrane database of systematic reviews · 2017
    Pooled it
  3. Pooled it
  4. Trial
  5. Severe Hypoglycemia and Incident Heart Failure Among Adults With Type 2 Diabetes.The Journal of clinical endocrinology and metabolism · 2022
    Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Effects of intensive glucose lowering in type 2 diabetes.The New England journal of medicine · 2008 · on this map
    Trial
  12. Trial
  13. Article
  14. Article
  15. Article
  16. The Phenotype of Elderly Patients with Type 2 Diabetes Mellitus and Poor Sleep Quality.International journal of environmental research and public health · 2020
    Observational
  17. Exposure to hypoglycemia and risk of stroke.Annals of the New York Academy of Sciences · 2018
    Review
  18. Article
  19. Article
  20. Continuous Glucose Monitoring Systems: A Review.Diagnostics (Basel, Switzerland) · 2013
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 12 institutions in 3 countries.

Denise E BondsDepartment of Public Health Sciences, University of Virginia School of Medicine, Charlottesville, Virginia 22908, USA. dbonds@virginia.edu
Ella Mae Kurashige
Richard Bergenstal
David Brillon
Michael Domanski
James V Felicetta
Vivian A Fonseca
Kathleen Hall
Irene Hramiak
Michael E Miller
Kwame Osei
Denise G Simons-Morton
ACCORD Study Group
Carl T. Hayden Veterans Affairs Medical Center · USCollege Medical Center · USDiabetes Australia · AUNational Heart Lung and Blood Institute · USPark Nicollet Clinic · USSt Joseph's Health Care · CAThrombosis and Atherosclerosis Research Institute · CATulane University · USUniversity of Minnesota · USUniversity of Virginia · USUniversity of Washington Applied Physics Laboratory · USWake Forest University · US

Funding

ZENARESTAT IN DIABETIC NEUROPATHYM01RR005096 · TULANE UNIVERSITY OF LOUISIANA · 1990 to 2005
$14.8M
PREVENTION OF CARDIOVASCULAR DISEASE IN DIABETES MELLITUN01HC095183 · MINNEAPOLIS MEDICAL RESEARCH FDN, INC. · 1999 to 2000
$1.9M
PREVENTION OF CARDIOVASCULAR DISEASE IN DIABETES MELLITUN01HC095181 · CASE WESTERN RESERVE UNIVERSITY · 1999 to 2000
$1.8M
PREVENTION OF CARDIOVASCULAR DISEASE IN DIABETES MELLITUN01HC095184 · COLUMBIA UNIVERSITY HEALTH SCIENCES · 1999 to 2000
$1.7M
PREVENTION OF CARDIOVASCULAR DISEASE IN DIABETES MELLITUN01HC095182 · WAKE FOREST UNIVERSITY · 1999 to 2000
$1.6M
PREVENTION OF CARDIOVASCULAR DISEASE IN DIABETES MELLITUS-N01HC95178N01HC095178 · WAKE FOREST UNIVERSITY HEALTH SCIENCES · 1999 to 2005
$1.5M
PREVENTION OF CARDIOVASCULAR DISEASE IN DIABETER MELLLITN01HC095180 · UNIVERSITY OF WASHINGTON · 1999 to 2000
$1.5M
PREVENTION OF CARDIOVASCULAR DISEASE IN DIABETES MELLITUN01HC095179 · MCMASTER UNIVERSITY · 1999 to 2000
$1.3M
NCRR NIH HHS 5M01RR05096NCRR NIH HHS M01RR0004741NHLBI NIH HHS N01-HC-95178NHLBI NIH HHS N01-HC-95179NHLBI NIH HHS N01-HC-95180NHLBI NIH HHS N01-HC-95181NHLBI NIH HHS N01-HC-95182NHLBI NIH HHS N01-HC-95183NHLBI NIH HHS N01-HC-95184NHLBI NIH HHS Y1-HC-1010NHLBI NIH HHS Y1-HC-9035
6 · The paper itself

Abstract

Hypoglycemia is a potentially serious side effect of blood glucose lowering in diabetes mellitus. The intensive glycemia treatment arm of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial is designed to treat patients with type 2 diabetes with target glycemia within the normal range (ie, glycosylated hemoglobin <6%). Because it is known that treating glycemia to such a low level in patients with diabetes will result in episodes of hypoglycemia, it is necessary to address prevention and treatment of such episodes to ensure patient safety. Thus, several approaches are being taken in the ACCORD trial to prevent initial episodes of severe hypoglycemia, to monitor the frequency of episodes that do occur, and to prevent recurrence. This report describes the processes used in the ACCORD trial, including the definition of severe hypoglycemia, the type of education provided to participants and staff members to prevent initial and subsequent episodes of severe hypoglycemia, and the monitoring systems implemented to identify severe hypoglycemia and prevent its recurrence. The ACCORD trial conducts review and oversight of individual cases of severe hypoglycemia and monitors rates of severe hypoglycemia by clinical site and treatment arm. If the ACCORD intensive glycemia treatment is found to be efficacious in preventing cardiovascular disease events, assessment of the risk and benefit will be essential. In addition, translation of the principles behind the monitoring of severe hypoglycemia in ACCORD into feasible strategies for use in clinical practice will be needed.

Indexed as

Diabetes Mellitus, Type 2Blood GlucoseBlood Glucose Self-MonitoringCoronary Artery DiseaseDiabetic AngiopathiesHumansHypoglycemiaRandomized Controlled Trials as TopicRisk ManagementBlood Glucose

Identifiers

PMID17599428
OpenAlexW2074308333

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.